BiotechTube

Bemnifosbuvir-Ruzasvir + Sofosbuvir-Velpatasvir

Phase 3Recruiting
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

HEPATITIS C VIRUS CHRONIC INFECTION

Conditions

HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection, Hepatitis C

Trial Timeline

Jun 2, 2025 → Mar 1, 2027

NCT ID
NCT07037277

About Bemnifosbuvir-Ruzasvir + Sofosbuvir-Velpatasvir

Bemnifosbuvir-Ruzasvir + Sofosbuvir-Velpatasvir is a phase 3 stage product being developed by Atea Pharmaceuticals for HEPATITIS C VIRUS CHRONIC INFECTION. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07037277. Target conditions include HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection.

What happened to similar drugs?

20 of 20 similar drugs in HEPATITIS C VIRUS CHRONIC INFECTION were approved

Approved (20) Terminated (8) Active (0)
✅Pegasys® + Pegasys®Chugai PharmaceuticalApproved
✅Pegylated Interferon + RibavirinAstellas PharmaApproved
✅Glecaprevir-pibrentasvirAbbVieApproved
✅ABT450r-ABT267-ABT333 +/- RibavirinAbbVieApproved
✅PTV/r/OBV/DSVAbbVieApproved
✅SOF/LDV (sofosbuvir/ledipasvir) + PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only) + EBR/GZR (elbasvir/grazoprevir) + RibavirinAbbVieApproved
✅OBV/PTV/r and DSV + Placebo to match OBV/PTV/r and DSVAbbVieApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07037277Phase 3Recruiting

Competing Products

20 competing products in HEPATITIS C VIRUS CHRONIC INFECTION

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
32
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
32
TERN-101Terns PharmaceuticalsPhase 2
32
TERN-201Terns PharmaceuticalsPhase 1
26
IVA337 + IVA337 + PlaceboInventivaPhase 2
29
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
29
IVA337 + PlaceboInventivaPhase 3
41
Pegasys® + Pegasys®Chugai PharmaceuticalApproved
43
peginterferon alfa-2a + rivavirinChugai PharmaceuticalPhase 3
40
SOF + COPEChugai PharmaceuticalPre-clinical
26
Colesevelam HclDaiichi SankyoPhase 2
35
ASP9831 + PlaceboAstellas PharmaPhase 2
35
FK788Astellas PharmaPhase 2
35
MK-2248MerckPhase 1
29
Interferon alfacon-1Astellas PharmaPhase 3
40
Pegylated Interferon + RibavirinAstellas PharmaApproved
35
Tacrolimus + steroids, monoclonal anti-IL2R antibodyAstellas PharmaPhase 2
35
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
29
Dolutegravir + MethadoneShionogiPhase 1
29
Clevudine + AdefovirEisaiPhase 3
40